

Dissecting the Decision

Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive, HER2-Negative Metastatic Breast Cancer

Video Program

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

Individualized treatment decisions for patients with metastatic breast cancer are driven by disease and patient characteristics. Estrogen receptor (ER)-positive disease, which represents approximately 65% of all cases, is perhaps the most nuanced in regard to therapeutic decision-making in the advanced-disease setting. In recent years, several groundbreaking clinical data sets and related FDA actions have significantly and unprecedentedly altered the treatment algorithm for patients with ER-positive metastatic breast cancer. Foremost among these developments have been the recent FDA approvals of the cyclin-dependent kinase (CDK) 4 and 6 inhibitors palbociclib, ribociclib and abemaciclib. Many areas of controversy and educational need exist within community practice, specifically in the management of ER-positive metastatic disease and the integration of CDK4/6 inhibitors into routine care. This program will present the perspectives of leading clinical investigators to provide clinicians with therapeutic strategies to address the disparate needs of patients with ER-positive metastatic breast cancer. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of these patients.

LEARNING OBJECTIVES

- Appraise the mechanism by which the CDK pathway contributes to breast cancer proliferation and growth, and recognize how the inhibition of CDK4/6 has improved outcomes for patients with ER-positive metastatic disease.
- Implement a clinical plan for the management of ER-positive metastatic breast cancer, considering the patient's clinical presentation, prior treatment course and psychosocial status.
- Assess how the FDA-approved CDK4/6 inhibitors abemaciclib, palbociclib and ribociclib can be optimally integrated into the management of ER-positive metastatic breast cancer.

- Develop an optimal approach to local and systemic therapy for patients with ER-positive breast cancer and CNS metastases, considering the implications of symptomatology, number of lesions and other factors.
- Appreciate the unique side effects associated with CDK4/6 inhibitors, and develop preventive and emergent strategies to reduce or ameliorate these toxicities.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at [ResearchToPractice.com/Privacy-Policy](https://www.researchtopractice.com/Privacy-Policy) for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at [ResearchToPractice.com/ERMBC19/Video/CME](https://www.researchtopractice.com/ERMBC19/Video/CME). The corresponding audio program is available as an alternative at [ResearchToPractice.com/ERMBC19](https://www.researchtopractice.com/ERMBC19).

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Co-Chair

Sara M Tolaney, MD, MPH

Associate Director
Susan F Smith Center for Women's Cancers
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: AstraZeneca Pharmaceuticals LP, Celldex Therapeutics Inc, Eisai Inc, Genentech, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi Genzyme; **Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Eisai Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Tesaro; **Contracted Research:** AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Roche Laboratories Inc.

Faculty

Neelima Denduluri, MD

Associate Chair
US Oncology Breast Cancer Research Committee
Medical Oncologist
Virginia Cancer Specialists
Arlington, Virginia

Advisory Committee: Daiichi Sankyo Inc; **Contracted Research:** Amgen Inc, Genentech, GTx Inc, Novartis; **Unpaid Consulting Agreement:** Genomic Health Inc.

Shom Goel, MBBS, PhD

Instructor in Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Advisory Committee: G1 Therapeutics, Lilly, Novartis; **Consulting Agreements, Contracted Research and Speakers Bureau:** Lilly.

Erika Hamilton, MD

Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Flatiron Health, Genentech, Lilly, Mersana Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics; **Contracted Research:** AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ArQule Inc, AstraZeneca Pharmaceuticals LP, BerGenBio ASA, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, H3 Biomedicine Inc, Hutchison MediPharma, Immunomedics Inc, InventisBio, Kadmon Holdings Inc, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Mallinckrodt Pharmaceuticals, Marker Therapeutics Inc, Medivation Inc, a Pfizer Company, Mersana Therapeutics, Merus BV, Novartis, NuCana, OncoMed Pharmaceuticals Inc, Pfizer Inc, PharmaMar, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Roche Laboratories Inc, Seattle Genetics, Stemcentrx, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, TetraLogic Pharmaceuticals, Verastem Inc, Zymeworks; **Paid Travel:** Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, EMD Serono Inc, Foundation Medicine, Genentech, Genzyme Corporation, Guardant Health, Helsinn Group, Heron Therapeutics, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sysmex Corporation, Tesaro.

Komal Jhaveri, MD

Assistant Attending
Breast Medicine and Early Drug Development Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: ADC Therapeutics SA, Jounce Therapeutics, Novartis, Pfizer Inc, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc; **Contracted Research:** ADC Therapeutics SA, Debiopharm Group, Genentech, Lilly, Novartis, Novita Pharmaceuticals, Pfizer Inc; **Data and Safety Monitoring Board/Committee:** Synthon Pharmaceuticals Inc.

Ruth M O'Regan, MD

Professor of Medicine
Chief, Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Advisory Committee: bioTheranostics Inc, Genentech, Genomic Health Inc, Immunomedics Inc, MacroGenics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc; **Contracted Research:** Eisai Inc, Novartis, Pfizer Inc, Seattle Genetics.

MODERATOR — **Dr Love** is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie

Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Lilly.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: June 2019

Expiration date: June 2020

Select Publications

- André F et al. **Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the Phase 3 SOLAR-1 trial.** *Proc ESMO 2018;Abstract LBA3_PR.*
- Baselga J et al. **Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.** *Proc ASCO 2018;Abstract LBA1006.*
- Cristofanilli M et al. **Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.** *Eur J Cancer 2018;104:21-31.*
- Dickler MN et al. **MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.** *Clin Cancer Res 2017;23(17):5218-24.*
- Fasching PA et al. **Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3.** *Proc ESMO 2018;Abstract 2900.*
- Freedman RA, Tolane SM. **Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer.** *Breast Cancer Res Treat 2018;167(3):607-14.*
- Goetz MP et al. **MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer.** *J Clin Oncol 2017;35(32):3638-46.*
- Hortobagyi GN. **Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: A review of subgroup analyses from the MONALEESA-2 trial.** *Breast Cancer Res 2018;20(1):123.*
- Hortobagyi GN et al. **Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.** *Ann Oncol 2018;29(7):1541-7.*
- Jerusalem G et al. **Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: The BOLERO-6 randomized clinical trial.** *JAMA Oncol 2018;4(10):1367-74.*
- Mayer E et al. **PALLAS: PALbociclib CoLaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer.** San Antonio Breast Cancer Symposium 2017;Abstract OT3-05-08.
- Neven P et al. **Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.** *Proc ASCO 2018;Abstract 1002.*
- Regan MM et al. **Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.** *Proc ASCO 2018;Abstract 503.*
- Rimawi M et al; PERTAIN Study Group. **First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial.** *J Clin Oncol 2018;36(28):2826-35.*
- Rugo HS et al. **Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies.** *Eur J Cancer 2018;101:123-33.*
- Sestak I et al. **Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial.** *JAMA Oncol 2018;4(4):545-53.*
- Slamon DJ et al. **Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3.** *J Clin Oncol 2018;36(24):2465-72.*
- Sledge GW et al. **MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy.** *J Clin Oncol 2017;35(25):2875-84.*
- Sparano J et al. **TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene Recurrence Score.** *Proc ASCO 2018;Abstract LBA1.*
- Sparano JA et al. **Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.** *N Engl J Med 2018;379(2):111-21.*
- Turner NC et al. **Overall survival with palbociclib and fulvestrant in advanced breast cancer.** *N Engl J Med 2018;379(20):1926-36.*
- Tripathy D et al. **Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial.** *Lancet Oncol 2018;19(7):904-15.*